MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia by Daniela Asslaber, Josefina.

Slides:



Advertisements
Similar presentations
Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):
Advertisements

Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis by Thet Thet Lin, Boitelo T. Letsolo,
The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology by Pierre A. Buffet, Innocent Safeukui, Guillaume Deplaine,
The β2 integrin–kindlin-3 interaction is essential for T-cell homing but dispensable for T-cell activation in vivo by Vicky Louise Morrison, Matthew MacPherson,
CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,
The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase–dependent cleavage of calreticulin in AML patients by Sarah Mans, Yara Banz,
Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.
Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.
The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,
Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.
HOXA9 is required for survival in human MLL-rearranged acute leukemias by Joerg Faber, Andrei V. Krivtsov, Matthew C. Stubbs, Renee Wright, Tina N. Davis,
Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B- cell lymphomas by Lingchen Fu, Yen-Chiu Lin-Lee,
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,
VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.
Do HSCs divide asymmetrically?
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes by Rajendra N. Damle, Fabio.
Defects in DBA: more than meets the eye
Finding a diamond in the (mouse is) rough
Next-generation leukemia immunotherapy
by Yoko Otake, Sridharan Soundararajan, Tapas K. Sengupta, Ebenezer A
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
by Zhenping Zhu Blood Volume 108(6): September 15, 2006
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.
Rituximab-induced tumor cell agglutination
Tax fingerprint in adult T-cell leukemia
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.
Mechanisms of HIV-associated lymphocyte apoptosis
T regulatory cells turn on T regulatory cells
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
by Romina Gamberale, Jorge R. Geffner, Julieta Sanjurjo, Paula X
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
CD6 Ligation Modulates the Bcl-2/Bax Ratio and Protects Chronic Lymphocytic Leukemia B Cells From Apoptosis Induced by Anti-IgM by Lyda M. Osorio, Angelina.
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
by Wolfram Springer, Alexander von Ruecker, and Roswitha Dickerhoff
by Lewis Hsu, Bhalchandra Diwan, Jerrold M. Ward, and Constance T
Taking a leaf from the book of oral tolerance
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,
by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C
CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.
Patients’ priorities in selecting chronic lymphocytic leukemia treatments by Carol Mansfield, Anthony Masaquel, Jessie Sutphin, Elisa Weiss, Meghan Gutierrez,
by Giridharan Ramsingh, Meagan A. Jacoby, Jin Shao, Rigoberto E
Lymphoma spread? Target CD47-SIRPα!
Yang et al. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood. 2008;112(3):805–813. Blood Volume 114(14): October.
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia by Zachary A. Hing, Rose Mantel,
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J
BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The Eμ-TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent.
by Silvia Mele, Stephen Devereux, Andrea G
by Geling Li, Emily Waite, and Julie Wolfson
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia by Ross Kinstrie, Dimitris Karamitros, Nicolas Goardon, Heather Morrison,
Changes throughout time in the lineage content of clones regenerated in secondary mice. Changes throughout time in the lineage content of clones regenerated.
High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib. by Richard.
A and B: Flow cytometric analysis of the effect of MRP-8/14 in the serum of a type 1 diabetic patient on the surface expression of CD11b and CD118. A and.
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
Mary Eapen  Biology of Blood and Marrow Transplantation 
How I treat refractory and early relapsed acute myeloid leukemia
Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11.
Patient Tregs express normal levels of suppression.
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.
Cold agglutinin disease
Overexpression of SUFU and GLI1 in the poor clinical outcome subgroup was confirmed by real-time PCR along with its association with disease progression.
Presentation transcript:

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia by Daniela Asslaber, Josefina D. Piñón, Irina Seyfried, Petra Desch, Markus Stöcher, Inge Tinhofer, Alexander Egle, Olaf Merkel, and Richard Greil Blood Volume 115(21): May 27, 2010 ©2010 by American Society of Hematology

miR-34a expression in CD19+ B cells of TCL1 transgenic mice and B-CLL patients both normalized to the corresponding healthy controls. Daniela Asslaber et al. Blood 2010;115: ©2010 by American Society of Hematology

miR-34a expression in CD19+ B-CLL cells normalized to CD19+ B cells of healthy controls. Daniela Asslaber et al. Blood 2010;115: ©2010 by American Society of Hematology

Treatment-free survival of B-CLL patients with or without alterations in the p53 axis. Daniela Asslaber et al. Blood 2010;115: ©2010 by American Society of Hematology

Physiologic functions of miR-34a in primary B-CLL cells and the prolymphocytic MEC1 cell line. Daniela Asslaber et al. Blood 2010;115: ©2010 by American Society of Hematology

Experimental determination of aberrations along the p53 axis. Daniela Asslaber et al. Blood 2010;115: ©2010 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.